OR5I1 and cancer: In addition to the targets listed in Table S1, for which commercial inhibitors are available, we included five other candidates from the top 100 dropped-out genes list (Supplementary Data 1, Supplementary 1 Tables) in our siRNA experiments: NDNF, NOSIP, and PDAP1, since they appeared in more than one of the four 25 gene groups (Supplementary Data 1, Supplementary 1 Tables), and two OR genes, OR5I1 and OR4D6, due to recent evidences that potentiate ORs  as targets in cancer therapy34.